D-天冬氨酸 4-叔丁酯 | 64960-75-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天冬氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-天冬氨酸 4-叔丁酯
• 中文别名: D-天冬氨酸4-叔丁酯；D-天冬氨酸4-叔丁酯,D-天门冬氨酸4-叔丁酯；DL-正亮氨酸；D-天冬氨酸-4-叔丁酯；D-天门冬氨酸 4-叔丁酯；H-D-Asp(OtBu)-OH
• 英文名称: D-aspartic acid 4-tert-butyl ester
• 英文别名: H-D-Asp(OtBu)-OH；(2R)-2-amino-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• CAS: 64960-75-4
• 化学式: C₈H₁₅NO₄
• mdl: MFCD00077101
• 分子量: 189.211
• InChiKey: MXWMFBYWXMXRPD-RXMQYKEDSA-N

物化性质

• 沸点：
  318.7±37.0 °C(Predicted)
• 密度：
  1.162
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  94.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储温度应保持在0°C。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-D-Asp(otbu)-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-D-Asp(otbu)-oh
CAS number: 64960-75-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H15NO4
Molecular weight: 189.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

H-D-Asp(OtBu)-OH是一种天冬氨酸衍生物。

反应信息

• 作为反应物：
  描述：

  D-天冬氨酸 4-叔丁酯 在 10 wt% Pd(OH)2 on carbon 氢气 、 溶剂黄146 、 potassium hydroxide 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 0.58h， 生成 (R)-4-tert-butyl 1-methyl 2-(N-cyclopentylpent-4-enamido)succinate
  参考文献：
  名称：

  [EN] AZEPIN-DERIVATIVES AS DERIVATIVES AS G- PROTEIN COUPLED RECEPTOR (GPR43) AGONISTS
  [FR] NOUVEAUX COMPOSÉS, PROCÉDÉ D'UTILISATION DE CES COMPOSÉS ET COMPOSITION PHARMACEUTIQUE LES CONTENANT

  摘要：

  公开号：

  WO2011151436A3
• 作为产物：
  描述：

  (R)-di-tert-butyl 2-aminosuccinate 在 potassium phosphate buffer 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以82%的产率得到D-天冬氨酸 4-叔丁酯
  参考文献：
  名称：

  Enzyme-Catalyzed Regioselective Hydrolysis of Aspartate Diesters

  摘要：

  DOI：

  10.1021/jo00129a066

文献信息

• Synthesis and stability evaluation of novel peptidomimetic Caspase-1 inhibitors for topical application
  作者：Sandrine Chambon、Sandrine Talano、Corinne Millois、Laurence Dumais、Romain Pierre、Loic Tomas、Céline Mathieu、Anne-Laurence Ghilini、Nicolas Vanthuyne、Kevin Reverse、Anne Brethon、Vincent Rodeschini、Catherine Comino、Grégoire Mouis、Ghizlane El-Bazbouz、Laurence Clary、Jean-François Fournier、Claire Bouix-Peter、Craig S. Harris、Laurent F. Hennequin

  DOI：10.1016/j.tet.2018.07.029

  日期：2018.9

  During our search for topically-active Caspase-1 inhibitors, we identified a novel class of potent inhibitors based on a 1,3,5-trisubstituted uracil motif equipped with an l-aspartate semi-aldehyde derived warhead. In the literature, the majority of Caspase-1 inhibitors possessing the same warhead have been designed and evaluated for oral administration as the ethyl acetal pro-drug form. For our topical

  在我们寻找具有局部活性的Caspase-1抑制剂的过程中，我们基于配备有1-天冬氨酸半醛衍生的战斗部的1,3,5-三取代尿嘧啶基序，确定了一类新型的强效抑制剂。在文献中，大多数具有相同战斗部的Caspase-1抑制剂已被设计和评估为乙缩醛前药形式用于口服。对于我们的局部用药方案，前药乙缩醛形式在皮肤中并未完全水解，并且在许多标准的局部用赋形剂中不稳定，因此，在我们的药物发现计划中，我们不得不专注于该分子的实际半缩醛药物形式。 。我们的工作集中于局部赋形剂中最终药物分子的合成以及非手性和手性稳定性。
• [EN] BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] ACIDES BÊTA-AMINÉS SUBSTITUÉS EN BÊTA ET ANALOGUES À UTILISER EN TANT QU'AGENTS DE CHIMIOTHÉRAPIE ET LEURS UTILISATIONS
  申请人：QUADRIGA BIOSCIENCES INC

  公开号：WO2017024009A1

  公开（公告）日：2017-02-09

  β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

  β-取代β-氨基酸，β-取代β-氨基酸衍生物，β-取代β-氨基酸类似物和（生物）同位素以及它们作为化疗药物的用途被披露。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素是选择性LAT1/4F2hc底物，并在表达LAT1/4F2hc转运蛋白的肿瘤中表现出快速摄取和保留。还披露了合成β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物的方法以及使用这些化合物治疗癌症的方法。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物在表达LAT1/4F2hc转运蛋白的肿瘤细胞中表现出选择性摄取，并在体内给予受试者后在癌细胞中积累。β-取代β-氨基酸衍生物和β-取代β-氨基酸类似物和（生物）同位素对几种肿瘤类型表现出细胞毒性。
• The Substantial Improvement of Amphotericin B Selective Toxicity Upon Modification of Mycosamine with Bulky Substituents
  作者：Edward Borowski、Natalia Salewska、Joanna Boros-Majewska、Marcin Serocki、Izabela Chabowska、Maria J. Milewska、Dominik Ziętkowski、Sławomir Milewski

  DOI：10.2174/1573406415666181203114629

  日期：2020.1.16

  may result in diminishment of mammalian in vitro toxicity of thus prepared AmB derivatives. Methods: Twenty-eight derivatives of AmB were obtained upon chemical modification of the amino group of mycosamine residue. This set comprised 10 N-succinimidyl-, 4 N-benzyl-, 5 Nthioureidyl- and 9 N-aminoacyl derivatives. Parameters characterizing biological in vitro activity of novel compounds were determined

  背景：据推测，通过对抗生素分子进行化学修饰，可以改善抗真菌药两性霉素B（AmB）的不利选择性毒性。 目的：本研究的目的是验证以下假设：在抗生素的氨基糖部分引入庞大的取代基可能会导致由此制得的AmB衍生物的哺乳动物体外毒性降低。 方法：对麦考明胺残基的氨基进行化学修饰，得到28个AmB衍生物。该组包含10个N-琥珀酰亚胺基-，4个N-苄基-，5个N-硫脲基-和9个N-氨酰基衍生物。确定了表征新型化合物的生物体外活性的参数。 结果：所有新化合物均显示出低于AmB的体外抗真菌活性，但大多数对人红细胞和三种哺乳动物细胞系的细胞毒性均可以忽略不计。结果，与AmB相比，选择性毒性指数（STI = EH50 / IC50）反映了大多数新型抗真菌药的选择性毒性，特别是在5种化合物的情况下。具有最高STI的新型AmB衍生物以低于IC50s的浓度诱导白色念珠菌细胞大量钾流出，但以低于100μg/ mL的浓度不会触发人红细胞释放钾。
• SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20210061802A1

  公开（公告）日：2021-03-04

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: R 1 , R 2 , R 4 , R 5 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)的化合物或其盐，其中：R1、R2、R4、R5和m在此处被定义。还揭示了使用这些化合物来抑制二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
• BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20190161468A1

  公开（公告）日：2019-05-30

  It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain.

  本文提供了一种苯并螺环烷衍生物，以及其制备方法和用途。具体而言，本文提供了一种式（I）化合物，或其药用可接受的盐、立体异构体或溶剂化合物，以及其制备方法，并用于制备治疗疼痛药物的用途。